Skip to main content
. Author manuscript; available in PMC: 2017 Nov 15.
Published in final edited form as: Kidney Int Rep. 2016 Nov 4;2(2):201–211. doi: 10.1016/j.ekir.2016.10.008

Table 4.

Association of body composition categories with all-cause mortality in 11,616 participants of NHANES 1999–2004*

A. Mortality status through 2011
HR (95% CI)
Body
Composition
Model 1 Model 2 Model 3 Model 4

Entire cohort (n=11,616)

Non-sarcopenic
non-obese
Reference Reference Reference Reference
Sarcopenic 2.72 (2.25 to 3.29) 1.62 (1.33 to 1.99) 1.35 (1.10 to 1.67) 1.32 (1.06 to 1.66)
Obese 2.09 (1.74 to 2.50) 1.27 (1.05 to 1.52) 1.09 (0.90 to 1.32) 0.98 (0.81 to 1.18)
Sarcopenic-
obese
6.99 (5.65 to 8.65) 1.69 (1.38 to 2.06) 1.35 (1.09 to 1.66) 1.28 (1.04 to 1.57)

Participants with eGFR ≥60 mL/min/1.73m2 (n=10,515)

Non-sarcopenic
non-obese
Reference Reference Reference Reference
Sarcopenic 2.80 (2.14 to 3.66) 1.79 (1.37 to 2.35) 1.44 (1.07 to 1.93) 1.45 (1.07 to 1.97)
Obese 2.24 (1.78 to 2.81) 1.41 (1.12 to 1.77) 1.21 (0.96 to 1.54) 1.09 (0.87 to 1.37)
Sarcopenic-
obese
7.45 (5.65 to 9.82) 2.09 (1.61 to 2.70) 1.64 (1.26 to 2.13) 1.57 (1.19 to 2.05)

Participants with eGFR <60 mL/min/1.7 3m2 (n=1,101)

Non-sarcopenic
non-obese
Reference Reference Reference Reference
Sarcopenic 1.79 (1.32 to 2.44) 1.46 (1.06 to 2.02) 1.24 (0.89 to 1.71) 1.14 (0.80 to 1.64)
Obese 0.93 (0.72 to 1.19) 1.00 (0.77 to 1.30) 0.87 (0.67 to 1.12) 0.77 (0.59 to 1.01)
Sarcopenic-
obese
1.83 (1.34 to 2.48) 1.19 (0.88 to 1.62) 1.05 (0.75 to 1.46) 0.97 (0.70 to 1.35)

B. Mortality status through 2006

HR (95% CI)
Body
Composition
Model 1 Model 2 Model 3 Model 4

Entire cohort (n=11,616)

Non-sarcopenic
non-obese
Reference Reference Reference Reference
Sarcopenic 2.99 (2.34 to 3.83) 1.68 (1.29 to 2.19) 1.39 (1.03 to 1.87) 1.34 (1.00 to 1.83)
Obese 1.93 (1.51 to 2.47) 1.18 (0.92 to 1.50) 1.00 (0.77 to 1.28) 0.86 (0.67 to 1.12)
Sarcopenic-
obese
7.14 (5.43 to 9.40) 1.65 (1.18 to 2.30) 1.23 (0.83 to 1.84) 1.17 (0.81 to 1.70)

Participants with eGFR ≥60 mL/min/1.73m2 (n=10,515)

Non-sarcopenic
non-obese
Reference Reference Reference Reference
Sarcopenic 3.13 (2.20 to 4.48) 1.95 (1.38 to 2.75) 1.52 (1.02 to 2.26) 1.51 (1.00 to 2.30)
Obese 2.11 (1.53 to 2.90) 1.34 (0.97 to 1.85) 1.15 (0.83 to 1.60) 1.00 (0.71 to 1.40)
Sarcopenic-
obese
8.26 (5.51 to 12.38) 2.30 (1.42 to 3.72) 1.75 (1.07 to 2.87) 1.63 (1.02 to 2.61)

Participants with eGFR <60 mL/min/1.73m2 (n=1,101)

Non-obese non-
sarcopenic
Reference Reference Reference Reference
Sarcopenic 1.79 (1.17 to 2.74) 1.38 (0.87 to 2.18) 1.24 (0.80 to 1.90) 1.16 (0.74 to 1.81)
Obese 0.87 (0.62 to 1.24) 0.94 (0.68 to 1.29) 0.77 (0.55 to 1.07) 0.67 (0.47 to 0.95)
Sarcopenic-
obese
1.61 (1.03 to 2.50) 0.95 (0.57 to 1.58) 0.77 (0.48 to 1.23) 0.73 (0.46 to 1.17)
*

P-value for interaction by CKD status: A. Mortality through 2011: p=0.01; B. Mortality status through 2006: p=0.01

Abbreviations: HR, Hazard Ratio; CI, Confidence Interval; eGFR, estimated glomerular filtration rate; CKD, Chronic Kidney Disease.

Bold values indicate p<0.05.

Model 1: unadjusted

Model 2: adjusted for age, sex, race/ethnicity

Model 3: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than non-melanoma skin cancer), eGFR categories and log-transformed urine albumin-creatinine ratio

Model 4: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than non-melanoma skin cancer), eGFR categories, log-transformed urine albumin-creatinine ratio, serum albumin, log-transformed c-reactive protein